Newsroom
Top Results
Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023
PDF Version MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2023, after the market close on […]
Sight Sciences Announces Addition of New Director Catherine Mazzacco
PDF Version MENLO PARK, Calif., June 09, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces that Catherine Mazzacco was elected to the Company’s board of directors at its Annual Meeting […]
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
PDF Version MENLO PARK, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2023 and reaffirmed guidance for full […]
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
PDF Version MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May […]
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
PDF Version Ali Bauerlein Ali Bauerlein has been appointed Sight Sciences’ Chief Financial Officer and Treasurer, effective April 3, 2023 MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ […]
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
PDF Version MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued financial […]
Sight Sciences Reports Third Quarter 2022 Financial Results
PDF Version MENLO PARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2022. Recent Business Highlights Generated total revenue of $18.7 million in […]
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
Multicenter Clinical Data from Five US sites Published in International Ophthalmology Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time. During 3 to 42 months follow-up, the majority of these standalone study patients treated with OMNI regained IOP control and avoided traditional surgery.